In the early morning of September 18, 2018, Swiss Therapeutics and US ViaCyte announced a strategic cooperation. They will jointly develop allogeneic stem cell therapies for disease treatment. With a transaction value of $25 million, ViaCyte will work with CRISPR Therapeutics to develop allogeneic stem cell products that can treat diabetes.
Under the agreement, ViaCyte will receive a patent license fee of 15 million, and CRISPR Therapeutics can decide whether to pay in cash or stock. In addition, ViaCyte can also receive an additional $10 million in the form of a convertible promissory note.
ViaCyte, a regenerative medicine company based in San Diego, is currently a leader in the field. Most people with diabetes use insulin drugs to relieve their condition. The medical community has also tried to completely treat it by transplanting a living pancreas, but the effect is general due to rejection.
ViaCyte has taken a different approach. For the first time in human history, they have attempted to construct a pancreatic cell device using human embryos to treat diabetes through a artificially created "new pancreas."
CRISPR Therapeutics, one of the three largest listed companies in the field of CRISPR (Editas, Intellia Therapeutics), is committed to providing genetic drugs for serious diseases.
The goal of the project is to use CRISPR-Cas9 to develop allogeneic stem cells that can escape the immune system. The candidate for ViaCyte is a stem cell-based islet cell replacement therapy. The main candidate product PEC-DirectPEC-Direct can be used for ViaCyte's PEC-01? Pancreatic progenitor cells are provided directly to vascularized cells by an implantable device. Used in conjunction with the maintenance of immunosuppressive therapy, PEC-Direct provides continuous functional therapy for patients with type 1 diabetes who are at high risk for acute life-threatening complications.
In the last week of the announcement, the federal court team supported the Broad Institute in a patent lawsuit at the University of California Berkeley and the Broad Institute. Although it was not clear which institution first invented the CRISPR-Cas9 technology, the federal court's ruling found that the Broad Institute was the first to obtain a patent, which made UC Berkeley almost no appeal.
CRISPR Therapeutics co-founder Emmanuelle Charpentier is from the University of California at Berkeley. She was part of a laboratory with Jennifer Doudna, one of the protagonists of the CRISPR patent war.
After Doudna and Zhang Feng parted ways, they all claimed to have invented the CRISPR technology. Doudna always said that Charpentier shared this honor with himself. The licensing of the Therapeutics is also from the University of California at Berkeley.
In addition to CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences received technical licenses from the University of California at Berkeley, while Editas Medicines received permission from the Broad Institute.
However, from the performance of last week, CRISPR Therapeutics, Intellia and Editas have not been greatly affected. However, at the time of writing, CRISPR Therapeutics dropped from $55.31 to $50.32, a 9.1% decline.
Gelatin Size 0 Empty Capsule,Empty Shell Gelatin Capsule,Empty Gelatin Color Hard Capsules,Colorful Capsule Empty Gelatin
Ningbo Jiangnan Capsule Co., Ltd. , https://www.ningbocapsule.com